Pertussis Vaccine
drug drugOn this page
Also known as Adsorbed purified pertussis vaccineBordetella pertussisHaemophilus pertussis wholeHemophilus pertussis wholeMicrobe de la coqueluche wholePertussispurified antigen
Summary
Pertussis Vaccine (CHEMBL2109219) is a phase-3 clinical-stage vaccine component (ATC J07AJ52); indicated across 9 conditions including pertussis and tetanus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- ATC class: J07AJ52 (+1 more)
- Indications: 9 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109219 |
| Name | Pertussis Vaccine |
| Type | Vaccine component |
| Max phase | 3 |
| ATC | J07AJ52, J07AJ02 |
Also known as: Adsorbed purified pertussis vaccine, Bordetella pertussis, Haemophilus pertussis whole, Hemophilus pertussis whole, Microbe de la coqueluche whole, Pertussis vaccine, Pertussis, purified antigen, PERTUSSIS VACCINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| pertussis | 3 | MONDO:0005077 | EFO:0000650 |
| tetanus | 3 | MONDO:0005526 | EFO:0005593 |
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| meningococcal meningitis | 3 | MONDO:0018059 | EFO:1001040 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| streptococcal infection | 2 | MONDO:0021680 | EFO:1001476 |
| pneumococcal infection | 1 | MONDO:0005114 | EFO:0000772 |
| Alzheimer disease | 1 | MONDO:0004975 | MONDO:0004975 |
| typhoid fever | 1 | MONDO:0005619 | EFO:0006789 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
| Not specified | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01439165 | PHASE4 | COMPLETED | Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose |
| NCT01698346 | PHASE4 | COMPLETED | Pertussis (Tdap) Vaccination in Pregnancy |
| NCT02783170 | PHASE4 | COMPLETED | Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women |
| NCT05136599 | PHASE1 | COMPLETED | Establishing a Controlled Human Infection Model of Bordetella Pertussis |
| NCT05847322 | Not specified | RECRUITING | Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks |
| NCT03751514 | Not specified | UNKNOWN | Bordetella Pertussis Colonisation Challenge Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: pertussis, tetanus, relapsing-remitting multiple sclerosis, meningococcal meningitis, multiple sclerosis, streptococcal infection